IDYA: IDEAYA Biosciences, Inc.
About
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
Current Value
$25.671 Year Return
Current Value
$25.671 Year Return
Key Details
Market Cap
$2.24B
P/E Ratio
-11.12
1Y Stock Return
-15.21%
1Y Revenue Growth
-83.30%
Dividend Yield
0.00%
Price to Book
1.9
Strategies that include IDYA
Stock's related to IDYA
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PGEN | 49.13% | $228.91M | -28.00% | 0.00% |
| ALEC | 47.29% | $377.04M | -19.46% | 0.00% |
| PLRX | 47.20% | $778.32M | -9.55% | 0.00% |
| CIEN | 46.93% | $9.69B | +47.41% | 0.00% |
| VSH | 45.25% | $2.07B | -31.61% | 2.64% |
| RCKT | 45.12% | $1.20B | -39.83% | 0.00% |
| KN | 44.65% | $1.60B | +12.19% | 0.00% |
| RVMD | 43.85% | $9.50B | +171.62% | 0.00% |
| AIN | 43.01% | $2.61B | -0.13% | 1.26% |
| NTLA | 42.49% | $1.44B | -50.35% | 0.00% |
| VIR | 42.05% | $954.40M | -26.51% | 0.00% |
| KALV | 42.04% | $440.88M | +17.08% | 0.00% |
| FATE | 41.97% | $248.29M | -11.02% | 0.00% |
| SNDX | 41.92% | $1.35B | +2.87% | 0.00% |
| CNXN | 41.82% | $1.84B | +14.37% | 0.57% |
| RYTM | 41.57% | $3.69B | +79.50% | 0.00% |
| MORN | 41.13% | $14.36B | +21.83% | 0.49% |
| AKRO | 41.07% | $2.17B | +93.09% | 0.00% |
| DIOD | 40.89% | $2.53B | -20.36% | 0.00% |
| BZH | 40.73% | $1.02B | +22.71% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MKC | 0.03% | $20.21B | +15.19% | 2.23% |
| ZTO | 0.04% | $12.58B | -4.71% | 4.73% |
| GPRK | 0.09% | $440.00M | -9.95% | 6.37% |
| MOMO | 0.11% | $909.44M | +4.43% | 0.00% |
| HPK | 0.16% | $1.86B | -9.44% | 0.81% |
| LTM | 0.20% | $8.51B | -100.00% | <0.01% |
| CHD | 0.25% | $27.18B | +19.50% | 1.03% |
| BEST | -0.25% | $31.65M | +3.88% | 0.00% |
| WTI | 0.25% | $291.77M | -42.77% | 2.01% |
| LITB | 0.28% | $35.48M | -75.45% | 0.00% |
| WM | -0.36% | $87.92B | +27.58% | 1.34% |
| LUMO | -0.36% | $37.45M | +41.97% | 0.00% |
| MANU | -0.45% | $2.88B | -9.41% | 0.00% |
| CORZ | -0.49% | $4.60B | +3,201.26% | 0.00% |
| VNOM | -0.52% | $5.48B | +79.62% | 3.35% |
| LX | -0.53% | $446.80M | +57.07% | 4.21% |
| LMT | -0.56% | $126.40B | +18.99% | 2.36% |
| FLNG | 0.56% | $1.42B | -14.21% | 11.33% |
| CAPR | 0.57% | $839.37M | +532.19% | 0.00% |
| EOG | 0.62% | $76.03B | +10.19% | 2.70% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| K | -13.79% | $27.77B | +52.50% | 2.79% |
| HUSA | -13.43% | $16.69M | -11.56% | 0.00% |
| PULM | -10.63% | $19.83M | +202.98% | 0.00% |
| GIS | -10.55% | $34.85B | -2.91% | 3.78% |
| CPB | -10.00% | $12.96B | +7.08% | 3.40% |
| UUU | -9.51% | $4.97M | -41.89% | 0.00% |
| CYCN | -8.97% | $4.77M | -16.19% | 0.00% |
| PGR | -8.48% | $149.10B | +57.29% | 0.45% |
| PPC | -8.34% | $12.38B | +100.96% | 0.00% |
| TCTM | -7.94% | $8.10M | -42.99% | 0.00% |
| CBOE | -7.48% | $21.46B | +15.84% | 1.11% |
| SUZ | -6.83% | $13.00B | -2.96% | 2.27% |
| IMO | -6.78% | $39.72B | +31.84% | 2.23% |
| PDD | -6.64% | $163.43B | +0.29% | 0.00% |
| MSDL | -6.56% | $1.83B | +0.66% | 7.26% |
| ASPS | -6.45% | $22.36M | -80.26% | 0.00% |
| MNR | -6.35% | $1.66B | -10.71% | 15.90% |
| FENG | -5.80% | $13.37M | +96.77% | 0.00% |
| BTCT | -5.56% | $42.61M | +353.33% | 0.00% |
| NEUE | -5.36% | $40.93M | -34.13% | 0.00% |
ETF's related to IDYA
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 59.81% | $6.58B | 0.35% |
| PTH | 59.70% | $143.31M | 0.6% |
| IBB | 58.26% | $6.66B | 0.45% |
| RSPA | 56.26% | $273.87M | 0% |
| IWO | 55.44% | $12.56B | 0.24% |
| PBE | 55.21% | $258.53M | 0.58% |
| ISCG | 53.91% | $640.00M | 0.06% |
| IWC | 53.53% | $933.99M | 0.6% |
| VBK | 53.19% | $19.31B | 0.07% |
| NUSC | 52.74% | $1.27B | 0.31% |
| VTWO | 52.40% | $12.38B | 0.1% |
| GNOM | 52.36% | $70.59M | 0.5% |
| IWM | 52.35% | $75.73B | 0.19% |
| VXF | 52.31% | $21.54B | 0.06% |
| GSSC | 52.06% | $529.86M | 0.2% |
| ARKG | 51.99% | $1.13B | 0.75% |
| PSC | 51.77% | $702.17M | 0.38% |
| TMSL | 51.72% | $288.12M | 0.55% |
| ESML | 51.66% | $1.90B | 0.17% |
| FNY | 51.62% | $372.31M | 0.7% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| KCCA | 0.28% | $220.51M | 0.87% |
| XBIL | -0.58% | $637.70M | 0.15% |
| DBB | 0.69% | $126.37M | 0.77% |
| HIGH | 0.76% | $302.78M | 0.51% |
| MINT | 1.52% | $11.62B | 0.35% |
| CLOI | 1.96% | $715.40M | 0.4% |
| IVOL | 1.99% | $548.70M | 1.02% |
| GCC | -2.01% | $133.23M | 0.55% |
| SOYB | -2.02% | $27.32M | 0.22% |
| CMDY | -2.23% | $279.14M | 0.28% |
| CANE | 2.58% | $17.72M | 0.29% |
| IBDP | 2.66% | $2.11B | 0.1% |
| IBHD | 3.04% | $327.80M | 0.35% |
| HDRO | -3.07% | $164.26M | 0.3% |
| SHYD | 3.08% | $311.50M | 0.35% |
| BCI | -3.24% | $1.20B | 0.26% |
| FLRN | 3.42% | $2.33B | 0.15% |
| CCOR | -3.65% | $109.04M | 1.18% |
| BILZ | 3.67% | $563.02M | 0.14% |
| FTGC | -4.05% | $2.17B | 1.02% |
News
SeekingAlpha
Delcath's Q3 sales hit $10 million, unlocking $25 million for Phase 2 trials. Click here to find out my analysis of DCTH stock.
Yahoo
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the appointment of Stu Dorman as Chief Commercial Officer. Mr. Dorman has a track record of commercial success in numerous specialty disease areas with over 20 years of oncology and hematology experience.
Yahoo
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the Jefferies London Healthcare Conference and its plans to host an Investor R&D Day in December 2024.
Finnhub
BEIJING, China, South San Francisco - Biocytogen Pharmaceuticals Co., Ltd. , a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that IDEAYA Biosciences,...
Yahoo
BEIJING & SOUTH SAN FRANCISCO, Calif., November 11, 2024--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, has exercised the option for an exclusive worldwide license for Biocytogen's B7H3/PTK7 BsADC program, IDE034, and has
Yahoo
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the selection of IDE034, a potential first-in-class B7H3/PTK7 topo-I-payload BsADC, as a development candidate and the exercise of its option for an exclusive worldwide license from Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) for potential first-in-class B7H3/PTK7 BsADC program.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.